---

Q2FY26 Result Highlights Thyrocare Technologies delivered a strong Q2FY26 performance, reporting 22% YoY consolidated revenue growth and 48% YoY EBITDA growth while maintaining highest quality standards. Consolidated revenue was Rs 217 crore (+22% YoY) and standalone revenue Rs 202 crore (+24% YoY), with franchisee revenue Rs 125 crore (+20% YoY) and partnership revenue Rs 66 crore (+35% YoY); the company processed 53.3 million tests (+21% YoY), served 5 million patients (+12% YoY), and had 10,100+ active franchisees (+20% YoY). At the segment level, pathology revenue grew 24% YoY, franchise grew 20% YoY, and partnerships grew 35% YoY. Gross margin metrics improved materially—management noted gross margin % improved by 101 basis points YoY driven by operating efficiencies and procurement savings, and elsewhere referenced gross margin improved by 24% YoY in line with increased revenue and better margin mix. Normalized EBITDA% rose on better margins and operating leverage, with a reported improvement of ~460 basis points in normalized EBITDA% and normalized EBITDA improving 49% YoY (reported EBITDA 48% YoY). Profitability also strengthened with PBT up 69% YoY and PAT up 82% YoY. Costs included higher employee expenses primarily due to annual increments, ESOP cost recorded as a non-cash charge relating to parent ESOPs, and other expenses rising YoY largely from higher volumes. Cash generation was healthy: incremental cash from operations for H1 stood at Rs 38.04 crore (43% over H1 FY25) and total operating cash for H1 FY26 was Rs 127.12 crore; investing capex payout in H1FY26 was Rs 14.89 crore, and dividend payout in H1FY26 was Rs 111.24 crore.

Key conference call takeaways

Performance overview & corporate actions

• The company reported its highest-ever standalone quarterly revenue, crossing 200 crores, driven by strong performance in its core pathology business.
• Thyrocare demonstrated robust year-on-year growth of 22% at the consolidated level, significantly outperforming the pathology diagnostic industry’s average mid-teen growth rates.
• Franchise network expanded to its highest-ever base of over 10,100 active quarterly franchisees (up from 8,446 in the same quarter last year), indicating renewed partner interest and successful expansion into Tier-3 cities and beyond.
• Corporate actions: announced a bonus share issue in the ratio of 2:1 and an interim dividend of Rs 7 per equity share, reflecting confidence in future growth and commitment to rewarding shareholders.
• Significant operational efficiency improvements were highlighted, with gross margins expanding by 500 basis points year-on-year.

Financial metrics & cash / debt position

• Revenue: Rs 217 crores (Consolidated), representing a 22% year-on-year growth; standalone revenue crossed Rs 200 crores for the first time (24% YoY).
• Gross Margin: 72% (Consolidated); standalone gross margin 71.6%, an improvement of 500 bps YoY.
• EBITDA Margin: 36% (Standalone, normalized), an improvement of 470 bps YoY.
• Cash Flow: Generated Rs 127 crores from operating activities in H1 FY26, a 43% year-on-year growth.
• Debt Levels: The company remains debt-free with net cash and cash equivalents of over Rs 190 crores.

Operating performance — business segments (pathology, franchise, partnerships, radiology, B2G, international)

• Pathology Business: primary growth driver; recorded 24% YoY revenue increase, attributed to franchise expansion, strong partnerships performance, and a resilient core business despite seasonal fever-related testing declines. Processed 53.3 million tests (+21% YoY) and served 5 million patients (+12% YoY) during the quarter.
• Franchise Business: revenue grew 20% YoY, driven by expansion of franchise base to over 10,100 active partners; company’s pay-for-performance and slab-based pricing incentivized franchisees, especially those added after FY22.
• Partnerships Business: representing online channels and API/pharmacy diagnostics, delivered ~35% YoY revenue growth and grew 36% YoY as a key part of the segment.
• Radiology Business: posted a modest revenue growth of 3% YoY for active centers; strategic focus shifted from aggressive growth to enhancing profitability and optimizing overheads, leading to dramatic profitability improvement.
• B2G (Business-to-Government): remains a small part of the business (~1% of total revenue, approx. Rs 2 crores in the quarter), focused on specialised projects (e.g., TB testing in Gujarat and Maharashtra). Broader B2G contracts are margin-dilutive.
• International Business (Tanzania): nascent but promising, growing 30% quarter-on-quarter; management expects revenues to double this year and anticipates operating break-even within 18–24 months.

Key discussions & insights — margins, growth strategy, quality, inorganic growth, GLP-1, GST

• Business model clarification: franchise network comprises hospitals, nursing homes, standalone labs and collection centers; of 10,100+ franchisees, ~1,000 are fully Thyrocare-branded contributing ~40% of franchise revenue; franchise partners largely handle sample collection while partnership business relies on Thyrocare’s dedicated fleet of ~1,900 phlebotomists.
• Gross margin improvement drivers: the 500 bps YoY improvement was driven by three reasons: (1) reduction in repeat test rates and sample wastage, (2) better procurement savings from negotiating higher volumes with vendors, and (3) a favorable product mix.
• Growth strategy & market dynamics: growth is bifurcated geographically — offline franchise growth strongest in Tier-2 cities and beyond, while online-driven partnerships expand mainly in metros and Tier-1 cities; this dual-channel strategy helps capitalize on different market segments.
• Quality & operational excellence: moved towards a Six Sigma standard, reducing complaints per million from 11.8 in Q2FY25 to 3.8 in the current quarter; average report turnaround improved to 3.52 hours after sample receipt due to automation and streamlined workflows.
• Inorganic growth contribution: of the 24% standalone revenue growth, 22% was organic and 2% from recent acquisitions (Polo Lab, Vimta, Think Health). Integration of Polo and Vimta lab networks is complete, strengthening presence in North and South India.
• GLP-1 weight loss drugs opportunity: management identified rising popularity of GLP-1 drugs as a huge opportunity, confirmed Thyrocare is developing complementary testing packages for pre-therapy, during-therapy and post-therapy monitoring — but refrained from providing specific strategic tactics to maintain a competitive edge.
• GST impact: recent GST rate cut on certain imported reagents (primarily for biochemistry tests) impacted ~20–25% of the company’s revenue base; management confirmed the entire benefit was passed on to franchisees and partners by reducing prices for relevant tests, making the net impact on margins negligible as the benefit received on input costs was passed on.

Outlook & valuation

Thyrocare Technologies entered Q2FY26 with strong operational momentum and a reinforced strategic foundation. Its Q2FY26 performance underscores the resilience of its core business model, with robust growth in pathology volumes, expanding franchisee additions, and steady gains in radiology. The company’s consistent double-digit growth highlights its ability to outpace the broader diagnostics industry, which is expanding at early to mid-teen rates. A key differentiator remains Thyrocare’s B2B-led approach, enabling it to scale rapidly through franchisees, diagnostic operators, and Healthtech partnerships while maintaining cost leadership and operational efficiency. Management’s focus on onboarding established diagnostic operators ensures faster ramp-up and mitigates risks of underperformance, while a churn management system balances expansion with quality. Strategic additions such as the regional lab in Bhagalpur and partner labs in Kashmir and Roorkee strengthen penetration in underpenetrated regions, while the Tanzania venture signals international aspirations. Sustaining quality through Six Sigma benchmarks, rapid turnaround times, and advisory board engagement with clinicians will remain key to differentiating Thyrocare in a crowded landscape.

Product innovation is another pillar of growth. Expansion of the test menu—histopathology, HPLC, coagulation, and BioFire PCR panels—complements existing flagship brands Aarogyam, Jaanch, and Her Check. With rising lifestyle diseases, Jaanch has emerged as a fast-growing vertical, supported by data-backed initiatives such as the HbA1c study and seasonal fever panels. This positions Thyrocare to capture wallet share not only in preventive wellness but also in specialist and lifestyle diagnostics. Financially, the company is in a strong position, with normalized EBITDA margins consistently above 30%, reflecting structural cost advantages from automation, scale, and logistics integration. However, management has reiterated its philosophy of reinvesting excess margins into expansion, acquisitions, and technology to sustain long-term growth. The shift from reagent rental to capex procurement further demonstrates disciplined capital allocation and focus on transparency, even though dependence on imported reagents remains a structural cost risk.

Integration of Polo, Vimta, and Think Health is now complete, providing both expanded geographic reach and new service lines like ECG-at-home. International expansion, though nascent, aligns with Thyrocare’s broader ambition to be a global low-cost diagnostics leader. Overall, Thyrocare is well positioned to sustain industry-leading growth, supported by its robust franchise network, scalable model, product innovation, and quality-first approach.

Thyrocare’s results show strong top-line and margin expansion, operational leverage from franchise scaling, and improving unit economics across channels. The company is debt-free with healthy cash generation, making it well placed to continue franchise expansion and selective inorganic activity. Management’s emphasis on quality (Six Sigma), automation, and diversified channel strategies (franchise, partnerships, radiology, international) positions Thyrocare to capture growth across segments while keeping margins and complaints under control. Opportunities (GLP-1 testing, Tanzania expansion, inorganic bolstering of geographies) are balanced by execution needs and competitive dynamics; overall tone from management is constructive with clear focus on operational excellence and disciplined expansion. At CMP, the stock is trading at 38x FY27E. We recommend a HOLD rating on the stock.